Una S. Ryan - 04 Jun 2025 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Reporting relationship: Director
Issuer ticker: QNCX
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jun 2025, 17:52:41 UTC
Prior SEC filing: 02 Oct 2024
Next SEC filing: 02 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Brendan Hannah as attorney-in-fact for Una S. Ryan

Key filing fact

Una S. Ryan filed Form 4 for Quince Therapeutics, Inc. (QNCX) on 06 Jun 2025.

Key facts

This page summarizes Una S. Ryan's Form 4 filing for Quince Therapeutics, Inc. (QNCX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jun 2025, 17:52.

Change

Previous filing in this sequence was filed on 02 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001255349 Primary reporting owner

RYAN UNA S

Relationship: Director
Address: C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Signature: /s/ Brendan Hannah as attorney-in-fact for Una S. Ryan
Signature date: 06 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNCX transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +27,000
Change %
Price: $0.000000
Shares after: 27,000
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,000
Exercise price: $1.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.